(Q35198028)

7 August 2017

1 reference

title

Animal models of stroke: do they have value for discovering neuroprotective agents? (English)

1 reference

7 August 2017

A Richard Green

1

1 reference

7 August 2017

Tomas Odergren

series ordinal

2

1 reference

7 August 2017

Tim Ashwood

series ordinal

3

1 reference

7 August 2017

publication date

1 August 2003

1 reference

Trends in Pharmacological Sciences

7 August 2017

published in

1 reference

7 August 2017

volume

24

1 reference

7 August 2017

issue

8

1 reference

7 August 2017

page(s)

402-408

1 reference

7 August 2017

cites work

Epidemiology of stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Trends in acute ischemic stroke trials through the 20th century

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Techniques for examining neuroprotective drugs in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Animal models of focal and global cerebral ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Thrombolysis of cerebral clot embolism in rat: effect of treatment delay

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Efficacy of intra-arterial and intravenous prourokinase in an embolic stroke model evaluated by diffusion-perfusion magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

MRI study on delayed ancrod therapy of focal cerebral ischaemia in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Tissue plasminogen activator for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Treatment of acute ischemic stroke: Part I: recanalization strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Hyperglycemic exacerbation of neuronal damage following forebrain ischemia: microglial, astrocytic and endothelial alterations.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Hyperglycemia and early reperfusion therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Therapeutic implications of hypothermic and hyperthermic temperature conditions in stroke patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Feasibility and safety of moderate hypothermia after massive hemispheric infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Influence of admission body temperature on stroke mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Admission body temperature predicts long-term mortality after acute stroke: the Copenhagen Stroke Study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Aggravation of acute ischemic stroke by hyperthermia is related to an excitotoxic mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Calcium antagonists for ischemic stroke: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Effect of intravenous nimodipine on blood pressure and outcome after acute stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Quantitative assessment of early brain damage in a rat model of focal cerebral ischaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Clinical experience with excitatory amino acid antagonist drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Clomethiazole is neuroprotective in models of global and focal cerebral ischemia when infused at doses producing clinically relevant plasma concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Pathobiology of ischaemic stroke: an integrated view

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

A comparative analysis of the neuroprotective properties of competitive and uncompetitive N-methyl-D-aspartate receptor antagonists in vivo: implications for the process of excitotoxic degeneration and its therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Mapping the ischaemic penumbra with PET: implications for acute stroke treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

A new rat model of thrombotic focal cerebral ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Neuroprotection by 2-h postischemia administration of two free radical scavengers, alpha-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN), in rats subjected to focal embolic cerebral ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Delayed treatment with nicotinamide (vitamin B3) reduces the infarct volume following focal cerebral ischemia in spontaneously hypertensive rats, diabetic and non-diabetic Fischer 344 rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Long-term functional end points following middle cerebral artery occlusion in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Recommendations for standards regarding preclinical neuroprotective and restorative drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Drug development for stroke: importance of protecting cerebral white matter

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Topographical and quantitative assessment of white matter injury following a focal ischaemic lesion in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Duration of neuroprotective treatment for ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Recommendations for clinical trial evaluation of acute stroke therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Cervene (Nalmefene) in acute ischemic stroke : final results of a phase III efficacy study. The Cervene Stroke Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900192-5

7 January 2021

10.1016/S0165-6147(03)00192-5

Identifiers

DOI

1 reference

7 August 2017

1 reference